Background: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties regarding efficacy, in addition to increased risk of infection and elevated costs of treatment. Objective: The aims of our study were to investigate the epidemiology of patients that underwent surgery for HGG with CW implantation, in addition to the assessment of related complications, long-term overall survival (OS), and associated prognostic factors. Methods: Three different medical databases were screened for conducting a systematic review of the literature, according to the PRISMA statement guidelines, evaluating the role of BCNU wafer implantation in patients with newly diagnosed HGG. The search query was based on a combination of medical subject headings (MeSH): "high grade glioma " [MeSH] AND "Carmustine " [MeSH] and free text terms: "surgery " OR "BCNU wafer " OR "Gliadel " OR "systemic treatment options " OR "overall survival. " Results: The analysis of the meta-data demonstrated that there was a significant advantage in using CWs in newly diagnosed GBM in terms of OS, and a very low heterogeneity among the included studies [mean difference 2.64 (95% CI 0.85, 4.44); p = 0.004; I2149 = 0%]. Conversely, no significant difference between the two treatment groups in terms of PFS wad detected (p = 0.55). The analysis of complications showed a relatively higher rate in Carmustine implanted patients, although this difference was not significant (p = 0.53). Conclusions: This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable.

Carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option? / Ricciardi, Luca; Manini, Ivana; Cesselli, Daniela; Trungu, Sokol; Piazza, Amedeo; Mangraviti, Antonella; Miscusi, Massimo; Raco, Antonino; Ius, Tamara. - In: FRONTIERS IN NEUROLOGY. - ISSN 1664-2295. - 13:(2022). [10.3389/fneur.2022.884158]

Carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option?

Ricciardi, Luca
Primo
;
Trungu, Sokol;Piazza, Amedeo;Mangraviti, Antonella;Miscusi, Massimo;Raco, Antonino
Penultimo
;
Ius, Tamara
Ultimo
2022

Abstract

Background: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties regarding efficacy, in addition to increased risk of infection and elevated costs of treatment. Objective: The aims of our study were to investigate the epidemiology of patients that underwent surgery for HGG with CW implantation, in addition to the assessment of related complications, long-term overall survival (OS), and associated prognostic factors. Methods: Three different medical databases were screened for conducting a systematic review of the literature, according to the PRISMA statement guidelines, evaluating the role of BCNU wafer implantation in patients with newly diagnosed HGG. The search query was based on a combination of medical subject headings (MeSH): "high grade glioma " [MeSH] AND "Carmustine " [MeSH] and free text terms: "surgery " OR "BCNU wafer " OR "Gliadel " OR "systemic treatment options " OR "overall survival. " Results: The analysis of the meta-data demonstrated that there was a significant advantage in using CWs in newly diagnosed GBM in terms of OS, and a very low heterogeneity among the included studies [mean difference 2.64 (95% CI 0.85, 4.44); p = 0.004; I2149 = 0%]. Conversely, no significant difference between the two treatment groups in terms of PFS wad detected (p = 0.55). The analysis of complications showed a relatively higher rate in Carmustine implanted patients, although this difference was not significant (p = 0.53). Conclusions: This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable.
2022
carmustine; complications; extent of resection; glioma surgery; overall survival
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option? / Ricciardi, Luca; Manini, Ivana; Cesselli, Daniela; Trungu, Sokol; Piazza, Amedeo; Mangraviti, Antonella; Miscusi, Massimo; Raco, Antonino; Ius, Tamara. - In: FRONTIERS IN NEUROLOGY. - ISSN 1664-2295. - 13:(2022). [10.3389/fneur.2022.884158]
File allegati a questo prodotto
File Dimensione Formato  
Ricciardi_Carmustine wafers_2022.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 831.45 kB
Formato Adobe PDF
831.45 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1665234
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact